Resistance after viral failure on atazanavir-containing therapy: multinational clinical cohort (BMS AI424-128 — 'IMPACT') final analysis

Purpose of the study: Real world data on the development of drug resistance after virologic failure (VF) on a protease inhibitor (PI)-based antiretroviral (ARV) regimen are limited. The I50L substitution in protease is the primary mutation associated with atazanavir drug resistance. The primary objective was to compare the prevalence of I50L from VF patients on an unboosted atazanavir (ATV)-based regimen vs. those on a ritonavir-boosted ATV (ATV/r)-based regimen regardless of prior treatment history. Supp lement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-P134 Cite this article as: Zolopa et al.: Resistance after viral failure on atazanavir-containing therapy: multinational clinical cohort (BMS AI424- 128 — ‘IMPACT’) final analysis. Journal of the International AIDS Society 2010 13(Suppl 4):P134. Full text: PubMed Central:  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112910/